Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells

Table 1 Patient characteristics and cell products

	Patient 1	Patient 2	Patient 3	Patient 4
Patient characteristics
Age/sex	44/m	69/m	70/m	65/m
Disease	T-NHL	AML	SPL	MM
No. prior regimens	4	1	3	7
Donor	sister	son	daughter	son
Best response	CR	CR	CR	n.e.
a/c GVHD	-/-	-/n.e.	-/-	-/n.e.
Outcome	R/5 mo	R/2 mo	R/8 mo	e.d./6 wk
Cell dose (10 ⁶ /kg)
γδ T cells	2.98	0.99	1.23	3.48
NK cells	18.82	12.85	2.26	1.54
αβ T cells	1.74	1.14	2.06	0.70
CD4⁺ T cells	0.01	0.03	0.02	0.006
CD8⁺ T cells	0.04	0.06	0.004	0.02
Total	23.59	15.07	5.57	5.75
KIR-mm	+	-	+	+

T-NHL indicates T-cell Non-Hodgkin-Lymphoma; AML, Acute Myeloid Leukaemia; SPL, Secondary Plasma Cell Leukaemia; MM, Multiple Myeloma; a/c GVHD, acute/chronic graft-versus-host disease; R, relapse; n.e., not evaluable; e.d., early death; KIR-mm, KIR ligand incompatibility in the graft-versus-host direction.

ISSN: 1479-5876